While global neurotechnology races forward with groundbreaking clinical trials, China is taking aggressive steps to institutionalize and govern the industry.

The National Medical Products Administration (NMPA) has approved China's third brain-computer interface (BCI) medical device standard, marking the world's first BCI standard to incorporate artificial intelligence for processing electroencephalogram (EEG) data. Developed with the participation of Tianjin University's Brain-Computer Haihe Laboratory as a core drafting unit, this landmark standard is set to officially take effect on September 1, 2027.

This standard establishes rigorous technical requirements and testing methodologies across the entire lifecycle of BCI data, covering acquisition, processing, annotation, storage, and access. By doing so, the framework directly resolves persistent industry pain points such as unstandardized dataset quality control and inconsistent development processes.

This regulatory rollout forms part of a broader, systematic national strategy. Regulatory specialists from the national medical device technical evaluation center have outlined a full lifecycle regulatory framework spanning biocompatibility and multi-functional trigger risk management, while specialized testing authorities continue to build out concept, technical, and application specifications. Furthermore, China's National Medical Products Administration has integrated implantable brain-computer interface medical devices into the catalog of high-end medical devices for priority examination and approval, offering full-process guidance and green approval channels to accelerate product commercialization.

Tianjin University's research team reportedly anchors global leadership with the world's largest patent pool in brain-computer interaction, alongside leading global rankings in publication volume and core performance metrics including EEG recognition accuracy, command capacity, and information transfer rates.